Onco Actu du 9 juin 2020

	1. BIOLOGIE
When Cancer Cells Can’t Make Their Own Fat, They Eat More Of It, U of T Study Finds [University of Toronto] The study, published this week in the journal Nature Metabolism, is the first to investigate global changes in cancerous cells as they adapt to a shortfall of critical nutrients such as fat molecules, or lipids, which make up the cell’s outer envelope.
	4.11 DÉP., DIAG. & PRONO. - OVAIRE
RCSI research suggests that better detection of a type of ovarian cancer could lead to better treatments [RCSI] Instead of having an inherited mutated BRCA1 gene, some patients have this gene modified in a way that is thought to silence it. The researchers analysed 2,636 patients with ovarian cancer from 15 international studies to see if those with this silenced BRCA1 gene had similar outcomes to those with the mutated gene.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Preventing pancreatic cancer metastasis by keeping cells “sheltered in place” [Sanford Burnham Prebys] In the study, the scientists used a mouse model of pancreatic cancer to show that, in response to glutamine deficiency, a protein called Slug drives metastasis by activating the epithelial-mesenchymal transition, or EMT—the process cells use to free themselves from tightly packed tissue.
UC research points to potential new treatment for pancreatic cancer [University of Cincinnati] Researchers in this study have found that using a therapeutic compound, called SapC-DOPS, a nanovesicle (or a nanotechnology drug delivery system) made of microscopic components of a cell, to deliver a combined biomarker target therapy and standard chemotherapy for pancreatic cancer may show benefit to patients.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Microbiotica, Cambridge Researchers to Study Microbiome Impact on Immunotherapy Response [Genome Web] For its part of the collaboration, Wellcome Sanger Institute spinout Microbiotica will use its microbiome profiling and analysis platform together with data from two CUH-led clinical studies, MelResist and MITRE, to identify gut bacterial signatures associated with treatment response or resistance.
	5.12.6 IMMUNOTHÉRAPIES - AMM
FDA Approves Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma [ESMO] Evidence for efficacy is based on the results from the IMbrave150 study.
	5.2.1 PHARMA - PARTENARIATS
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer [Alphamab] KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two non-overlapping epitopes of HER2 and lead to a dual HER2 signal blockade, presumedly causing HER2 to aggregate on the cell surface and endocytose.
	5.2.3 PHARMA - ÉCONOMIE
The top 10 pharma R&D budgets in 2019 [Fierce Pharma] Looking through the main programs across all the top 10 companies, it’s immediately clear oncology is still the biggest therapeutic category when it comes to spending. Cancer R&D has traditionally been expensive, but the FDA’s willingness to approve treatments on more limited data is cutting costs and offering a quicker path to market.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
New guidance helps select breast cancer patients for urgent surgery or chemotherapy during pandemic [Royal Marsden] The innovative algorithm, using data from multiple international trials, can identify postmenopausal patients with primary ER+HER2- breast cancer (c.70% of cases) who have less endocrine-sensitive tumours and who should be prioritised for early surgery or neoadjuvant chemotherapy.
Global oncology pharmacists face restricted access to essential PPE items, UCI study finds [UCI] In the Journal of Oncology Pharmacy Practice, Alexandre Chan, department chair and professor clinical pharmacy practice, and Canadian and Australian colleagues of the International Society of Oncology Pharmacy Practitioners surveyed 42 pharmacy practice groups in 28 countries and regions (in both developed and developing countries) to determine pain points that this global pandemic has created for oncology pharmacy practitioners.